Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to lymphokine – cytokine – or other secreted growth...
Reexamination Certificate
2009-03-03
2010-12-28
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to lymphokine, cytokine, or other secreted growth...
C424S001490, C424S133100, C424S134100, C424S143100, C424S145100, C424S152100, C424S153100, C424S155100, C424S178100, C424S179100, C424S192100, C424S193100, C530S391100, C530S391300, C530S391700, C530S388230
Reexamination Certificate
active
07858070
ABSTRACT:
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.
REFERENCES:
patent: 6524854 (2003-02-01), Monia et al.
patent: 7432342 (2008-10-01), Braun et al.
patent: 7534866 (2009-05-01), Chang et al.
patent: 7550143 (2009-06-01), Chang et al.
patent: 7591994 (2009-09-01), Govindan et al.
patent: 2003/0198956 (2003-10-01), Makowski et al.
patent: 2004/0018587 (2004-01-01), Makowski et al.
patent: 2005/0003403 (2005-01-01), Rossi et al.
patent: 2006/0228300 (2006-10-01), Chang et al.
patent: 2006/0228357 (2006-10-01), Chang et al.
patent: 2007/0086942 (2007-04-01), Chang et al.
patent: 2009/0202433 (2009-08-01), Chang et al.
patent: 2009/0202487 (2009-08-01), Chang et al.
patent: 2009/0304580 (2009-12-01), Goldenberg et al.
patent: 2010/0068137 (2010-03-01), Chang et al.
patent: 2010/0189641 (2010-07-01), Chang et al.
patent: 2010/0189689 (2010-07-01), Chang et al.
patent: 2010/0196266 (2010-08-01), Goldenberg et al.
patent: WO2007075270 (2007-07-01), None
Alto et al. “Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring”, PNAS USA 100:4445-50, 2003.
Backer et al. “Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins”, Bioconjugate Chem., 17 (4), pp. 912-919, 2006.
Banky et al. “Dimerization/Docking Domain of the Type lα Regulatory Subunit of cAMP-dependent Protein Kinase”, J. Biol. Chem. 273:35048-55, 1998.
Carr et al. “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 266:14188-92 (1991).
Chang et al. “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity”, Clin. Cancer Res. 13:5586s-5591s, 2007.
Colledge et al. “AKAPs: from structure to function”, Trends Cell Biol. 6:216-21 (1999).
Corbin et al. “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase”, J. Biol. Chem. 248:1813-21 (1973).
Gold et al. “A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma”, Cancer Res. 68:4819-26, 2008.
Goldenberg et al. “Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting”, J. Nucl. Med. 49:158-63, 2008.
Hausken et al. “Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII”, J. Biol. Chem. 271:29016-22 (1996).
Hodneland et al. “Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands”, Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.
Lohmann et al. “High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins”, Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).
Mason, Anthony J. “Functional Analysis of the Cysteine Residues of Activin A”, Mol. Endocrinol. 8:325-32, 1994.
Newlon et al. “A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes”, EMBO J. 2001; 20:1651-1662.
Newlon et al. “The molecular basis for protein kinase A anchoring revealed by solution NMR”, Nature Struct. Biol. 1999; 3:222-227.
Ngo et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 491-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.
Oyen et al. “Human testis cDNA for the regulatory subunit Rllα of cAMP-dependent protein kinase encodes an alternate amino-terminal region”, FEBS Letters 246:57-64, 1989.
Rose et al. “Structural basis of dimerization, coactivator recognition and MODY3 mutations in Hnf-1α”, Nature Struct. Biol. 2000; 7:744-748.
Rossi et al. “Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics”, Cancer Res. 68:8384-92, 2008.
Rossi et al. “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting”, Proc. Natl. Acad. Sci. USA 103:6841-46, 2006.
Rustandi et al. “The Ca2+-Dependent Interaction of s100B(ββ) with a Peptide Derived from p53”, Biochemistry 1998; 37: 1951-1960.
Scott et al. “Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase”, J. Biol. Chem. 265:21561-66 (1990).
Sharkey et al. “Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non—Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody”, Cancer Res. 68:5282-90, 2008.
Sharkey et al. “Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model”, Radiology 246:497-507, 2008.
Stryer et al. “Levels of Structure in Protein Architecture”, Biochemistry, 3rd Ed., pp. 31-33, W.H. Freeman & Co., New York, 1988.
Winkler et al. “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody”, J. Immunol. 165:4505-14, 2000.
Wong et al. “AKAP Signalling Complexes: Focal Points in Space and Time”, Nat. Rev. Mol. Cell Biol. 12:959-70 (2004).
Zhu et al. “Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor”, Invest. New Drugs 17:195-212, 1999.
Burns-Hamuro et al. “Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange” Protein Science (2005), 14:2982-2992.
Carr et al. “Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to theType II Regulatory Subunit of PKA” J. Biol. Chem. 2001 276:17332-17338.
Gold et al. “Molecular Basis of AKAP Specificity for PKA Regulatory Subunits” Mol. Cell (2006) 24:383-395.
Hundsrucker et al. “High-affinity AKAP7δ—protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides” Biochem. J. (2006) 396:297-306.
Kinderman et al. “A Novel and Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-dependent Protein Kinase” Mol. Cell (2006) 24(3): 397-408.
Stokka et al. “Characterization of A-kinase-anchoring disruptors using a solution-based assay” Biochem. J. (2006) 400:493-499.
Chang Chien-Hsing
Goldenberg David M.
Rossi Edmund A.
Huynh Phuong
IBC Pharmaceuticals, Inc.
Nakashima Richard A.
LandOfFree
Multivalent immunoglobulin-based bioactive assemblies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent immunoglobulin-based bioactive assemblies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent immunoglobulin-based bioactive assemblies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223733